PDF(Pubmed)
Abstract：
UNASSIGNED: To describe fluorescein angiography (FA) parameters observed in premature neonates with retinopathy of prematurity (ROP).
UNASSIGNED: Retrospective case series.
UNASSIGNED: Patients with ROP who underwent FA imaging using Retcam at Holtz Children\'s Hospital from November 2014 to October 2022.
UNASSIGNED: Fluorescein angiography images of the included patients were analyzed with a focus on the timing of angiography phases, including choroidal flush, retinal, and recirculation phases. Gestational age, birth weight (BW), age at imaging, treatment choice, and any FA complications were documented.
UNASSIGNED: Dose of fluorescein administered, onset and duration of each angiography phase, and FA findings in ROP-treated patients.
UNASSIGNED: A total of 72 images of 72 eyes were reviewed. Image quality was deemed suitable for inclusion in 64 eyes (88.9%) of 43 patients. The mean gestational age and BW at birth were 24.4 ± 1.9 weeks and 607.8 ± 141.3 g, respectively. The mean postmenstrual age at FA imaging was 50.5 ± 40.8 weeks. All eyes (100%) received treatment with intravitreal injection of anti-VEGF at a mean age of 35.5 ± 2.4 weeks. The onset and duration of angiography phases were relatively variable within the cohort. Choroidal flush occurred at a mean time of 12.2 seconds (range: 6-22 seconds). A subsequent retinal phase was documented at a mean time of 11.96 seconds (range: 3-22 seconds). Recirculation phase was complete at an average time of 2.15 minutes (range: 1-5.45 minutes) postfluorescein injection. None of patients developed allergic reactions to fluorescein injection, such as rash, respiratory distress, tachycardia, fever, or local injection site reactions.
UNASSIGNED: Angiographic phases on FA in preterm infants with ROP are variable and may occur earlier than the established references for adults.
UNASSIGNED: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
UNASSIGNED: Retrospective case series.
UNASSIGNED: Patients with ROP who underwent FA imaging using Retcam at Holtz Children\'s Hospital from November 2014 to October 2022.
UNASSIGNED: Fluorescein angiography images of the included patients were analyzed with a focus on the timing of angiography phases, including choroidal flush, retinal, and recirculation phases. Gestational age, birth weight (BW), age at imaging, treatment choice, and any FA complications were documented.
UNASSIGNED: Dose of fluorescein administered, onset and duration of each angiography phase, and FA findings in ROP-treated patients.
UNASSIGNED: A total of 72 images of 72 eyes were reviewed. Image quality was deemed suitable for inclusion in 64 eyes (88.9%) of 43 patients. The mean gestational age and BW at birth were 24.4 ± 1.9 weeks and 607.8 ± 141.3 g, respectively. The mean postmenstrual age at FA imaging was 50.5 ± 40.8 weeks. All eyes (100%) received treatment with intravitreal injection of anti-VEGF at a mean age of 35.5 ± 2.4 weeks. The onset and duration of angiography phases were relatively variable within the cohort. Choroidal flush occurred at a mean time of 12.2 seconds (range: 6-22 seconds). A subsequent retinal phase was documented at a mean time of 11.96 seconds (range: 3-22 seconds). Recirculation phase was complete at an average time of 2.15 minutes (range: 1-5.45 minutes) postfluorescein injection. None of patients developed allergic reactions to fluorescein injection, such as rash, respiratory distress, tachycardia, fever, or local injection site reactions.
UNASSIGNED: Angiographic phases on FA in preterm infants with ROP are variable and may occur earlier than the established references for adults.
UNASSIGNED: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
摘要：
■描述在患有早产儿视网膜病变（ROP）的早产儿中观察到的荧光素血管造影（FA）参数。
■回顾性病例系列。
■2014年11月至2022年10月在Holtz儿童医院使用Retcam进行FA成像的ROP患者。
■对纳入患者的荧光血管造影图像进行了分析，重点是血管造影阶段的时机，包括脉络膜冲洗,视网膜,和再循环阶段。妊娠年龄,出生体重（BW），成像年龄，治疗选择,并记录任何FA并发症.
■施用的荧光素剂量，每个血管造影阶段的开始和持续时间，ROP治疗患者的FA结果。
■共观察72只眼睛的72张图像。图像质量被认为适合纳入43例患者的64只眼(88.9%)。出生时的平均胎龄和体重分别为24.4±1.9周和607.8±141.3g，分别。FA成像时的平均月经后年龄为50.5±40.8周。所有眼睛(100%)在平均年龄35.5±2.4周时接受玻璃体内注射抗VEGF治疗。血管造影阶段的开始和持续时间在队列中相对可变。脉络膜冲洗发生在12.2秒的平均时间(范围:6-22秒)。随后的视网膜阶段记录为11.96秒的平均时间(范围:3-22秒)。在荧光素注射后2.15分钟(范围:1-5.45分钟)的平均时间完成再循环阶段。没有患者对荧光素注射产生过敏反应，如皮疹，呼吸窘迫,心动过速,发烧,或局部注射部位反应。
■患有ROP的早产儿FA的血管造影阶段是可变的，并且可能比成人的既定参考更早发生。
■专有或商业披露可在本文末尾的脚注和披露中找到。
■回顾性病例系列。
■2014年11月至2022年10月在Holtz儿童医院使用Retcam进行FA成像的ROP患者。
■对纳入患者的荧光血管造影图像进行了分析，重点是血管造影阶段的时机，包括脉络膜冲洗,视网膜,和再循环阶段。妊娠年龄,出生体重（BW），成像年龄，治疗选择,并记录任何FA并发症.
■施用的荧光素剂量，每个血管造影阶段的开始和持续时间，ROP治疗患者的FA结果。
■共观察72只眼睛的72张图像。图像质量被认为适合纳入43例患者的64只眼(88.9%)。出生时的平均胎龄和体重分别为24.4±1.9周和607.8±141.3g，分别。FA成像时的平均月经后年龄为50.5±40.8周。所有眼睛(100%)在平均年龄35.5±2.4周时接受玻璃体内注射抗VEGF治疗。血管造影阶段的开始和持续时间在队列中相对可变。脉络膜冲洗发生在12.2秒的平均时间(范围:6-22秒)。随后的视网膜阶段记录为11.96秒的平均时间(范围:3-22秒)。在荧光素注射后2.15分钟(范围:1-5.45分钟)的平均时间完成再循环阶段。没有患者对荧光素注射产生过敏反应，如皮疹，呼吸窘迫,心动过速,发烧,或局部注射部位反应。
■患有ROP的早产儿FA的血管造影阶段是可变的，并且可能比成人的既定参考更早发生。
■专有或商业披露可在本文末尾的脚注和披露中找到。
